← Back to Search

Other

Hyperbaric Oxygen Treatment for Non-Hodgkin's Lymphoma (Auto-HBO Trial)

N/A
Waitlist Available
Led By Omar Aljitawi, MD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessment at: day -7 (lymphoma) or day -3 (myeloma), pre-hbo (day 0), pre-transplant (6-10hrs post-hbo), 24 and 48 hrs after starting hyperbaric oxygen treatment as well as 3 days post-neutrophil engraftment
Awards & highlights
No Placebo-Only Group

Summary

By doing this study, researchers hope to learn the following: * The safety of hyperbaric oxygen administration in the setting of the autologous transplant * The effects of hyperbaric oxygen administration on neutrophil count recovery and engraftment

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessment at: day -7 (lymphoma) or day -3 (myeloma), pre-hbo (day 0), pre-transplant (6-10hrs post-hbo), 24 and 48 hrs after starting hyperbaric oxygen treatment as well as 3 days post-neutrophil engraftment
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessment at: day -7 (lymphoma) or day -3 (myeloma), pre-hbo (day 0), pre-transplant (6-10hrs post-hbo), 24 and 48 hrs after starting hyperbaric oxygen treatment as well as 3 days post-neutrophil engraftment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Presence or absence of a treatment limiting toxicity
Secondary study objectives
Reduction in time to neutrophil recovery and engraftment post-cord blood transplant.
Other study objectives
Examine correlation between change to erythropoietin (EPO) levels and time to neutrophil recovery and engraftment.
Explore the effects of hyperbaric oxygen (HBO) therapy on erythropoietin (EPO) levels.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hyperbaric Oxygen TreatmentExperimental Treatment1 Intervention
Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Administration of hyperbaric oxygen
2013
N/A
~20

Find a Location

Who is running the clinical trial?

Southwest Oncology GroupNETWORK
388 Previous Clinical Trials
261,167 Total Patients Enrolled
University of Kansas Medical CenterLead Sponsor
506 Previous Clinical Trials
174,307 Total Patients Enrolled
SWOG Cancer Research NetworkNETWORK
397 Previous Clinical Trials
266,262 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top